AccuraGen Appoints George Cardoza as Chief Executive Officer

July 24, 2022

George Cardoza will be joining AccuraGen as its Chief Executive Officer and will also be joining the Board of Directors.

Several Experts Highly Recognized AccuraGen's Scientific Research

September 18, 2020

Several experts highly recognized AccuraGen's scientific research on early cancer detection.

NGS Roundtable Forum: Opportunities and Challenges of NGS

September 11, 2020

Kang Ying, CEO of AccuraGen Holdings participated in NGS roundtable forum and shared his perspectives on cancer screening.

AccuraGen China passed the proficiency test of 2019-nCoV nucleic acid testing

April 9, 2020

AccuraGen China passed the proficiency test of 2019-nCoV nucleic acid testing (NCCL)

Collaborative research on early detection of colorectal cancer unveiled at AGBT

February 28, 2020

AccuraGen unveil edits result of the collaborative research on the early detection of colorectal cancer at AGBT this year.

AccuraGen China passed the PT of 2019-nCoV nucleic acid testing

February 25, 2020

Shanghai Yunsheng Medical Laboratory hasactively participated in the 2019-nCoV nucleic acid detection capabilityverification organized by SCCL.

AccuraGen China Participated in the Campaign against 2019-nCoV

February 3, 2020

Shanghai Yunsheng Medical Laboratory participated in the campaign against 2019-nCoV on February 2nd.

Collaborator Presented New Data at ESMO 2019 Congress

October 9, 2019

Dr. Tao Fu presented new data as a poster at the ESMO 2019 Congress.

Several Collaborator Presented Research Result of Different Cancers

September 5, 2019

Several Collaborator Presented Research Result of Different Cancers

Collaborator Presented Research Result on Small Methods Journal

August 30, 2019

Research result conducted by Professor Jiatao Lou recently published on Small Methods.

AccuraGen Sponsored the 8th Annual Meeting of Chinese Pathologists

October 17, 2018

AccuraGen sponsored the session of "Writing and Publication of English Papers on Pathology" at the 8th Annual Meeting of Chinese Pathologists.

AccuraGen Passed CAP NGSST-PT with Full Marks Again

July 19, 2018

The NGS laboratory under AccuraGen Holdings passed the NGSST Proficiency Testing assessment launched by CAP with full marks again.

Shanghai Yunsheng Medical Laboratory joined the Inclusive Medical Association

May 14, 2018

Shanghai Yunsheng Medical Laboratory under AccuraGen Holdings participated in the launch of the Inclusive Medical Association.

Collaborator presented AccuraGen's ctDNA-NGS kit validation at AACR

April 25, 2018

The study was conducted by Professor Jiatao Lou, director of the Chest Hospital.

AccuraGen Clinical Laboratory obtained CAP accreditation

March 5, 2018

The High-throughput Sequencing (NGS) Laboratory of AccuraGen Holdings Group has been accredited by the College of American Pathologists (CAP).

AccuraGen passed the EQA of bioinformatics with full score

January 29, 2018

Shanghai Yunsheng Medical Laboratory Co., Ltd., a subsidiary of AccuraGen Holdings, passed the external quality evaluation with 100 marks.

AccuraGen was invited to PMWC to showcase the latest achievements in liquid biopsy

January 29, 2018

The Precision Medicine World Conference (PMWC) of 2018 was held in Silicon Valley from January 22 to 24 in the United States.

Science Overview

Blood as a window to our health

We have been understanding our health through a number of blood tests in a large spectrum of scenarios; ranging from diabetes to heart attack, from pregnancy to cancer. We track proteins, circulating DNA, miRNA, etc

Advance technology

With the advancement of technology, we can now capture and digitize analytes in our blood quantitatively. Firefly is the technology we built with many years of efforts to accurately convert signals from circulating tumor DNA to infer tumor load of an individual.

Multi-analytes modeling

By gathering multi-omics information from a large population of healthy and cancer cohort, we train with the state-of-the-art machine learning algorithm to differentiate cancer and healthy status of an individual. 

Transforming cancer management

The potential applications of liquid biopsy are vast - from targeted cancer therapy selection to real-time minimal residual disease monitoring to population-level early screening - and we believe it will play a critical role in the future of cancer management. With more clinical studies that we're collecting, we will show clincal utility for different applications. For the next person coming to our clinic, we will take a snapshot with his blood and try to catch cancer in a stage that can be treated.